Glossary of Global Health Agreement Terms
GHIAA has developed a glossary of global health agreement terms to facilitate discussion of the varying interpretations of commonly used global health terms. We welcome suggestions of new terms and definitions which are important to the global health policy and transactions community.
This glossary includes definitions of the key terms contained in public health related agreements, policies or publications and is intended to serve as a reference for the common definitions used in global health alliance agreements. The source for each definition is indicated after such definition.
Alternative One: An individual’s ability to obtain appropriate health care services. Barriers to access can be financial, geographic, organizational and sociological. Efforts to improve access often focus on providing/improving health coverage (U.S. Department of Health & Human Services, Office of the Assistant Secretary for Planning & Evaluation Glossary of Terms).
Alternative Two: The degree to which services can be obtained within the cost and effort limits that are acceptable to the general population (Global Health Learning Center Glossary).
Alternative Three: Having the product continuously available and affordable at public or private health facilities that are within one hour’s walk from the homes of the population (WHO Access to Affordable Essential Medicines).
Alternative Four: The ability to secure the product, at a specified level of quality, subject to a specified maximum level of personal inconvenience and cost, while in possession of a specified amount of information (Equity of Access to Health Care: Outlining the Foundations for Action.” )
Alternative Five: The potential for or actual entry of a population into the health system. Entry is dependent upon the wants, resources, and needs that individuals bring to the care-seeking process. The ability to obtain wanted or needed services may be influenced by many factors, including travel, distance, waiting time, available financial resources, and availability of a regular source of care. Access also refers to the extent to which a public health service is readily available to the community’s individuals in need. Accessibility also refers to the capacity of the agency to provide service in such a way as to reflect and honor the social and cultural characteristics of the community and focuses on agency efforts to reduce barriers to service utilization (Turnock, BJ. Public Health: What It Is and How It Works. Jones and Bartlett. 2009, cited in Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
Alternative One: the right to use results under the terms and conditions laid down in this Agreement. (IMI 2 Model Grant Agreement, §25.1).
Alternative Two: the rights to use. (IMI 1 Model Grant Agreement General Conditions, §II.1.1).
The chemical substance responsible for a product’s effect. (WHO Access to Medicines Glossary).
The geographic area of any country (i) where there is an Outbreak; (ii) for which there is an Increased Outbreak Preparation Need; or (iii) the Parties otherwise agree in writing and in each case, including healthcare workers providing healthcare in such a country regardless of their home country. (Unattributed Funder Development Partnering Agreement, §1.1.2 ).
Any Person which, directly or indirectly, is controlled by, controls or is under common control, with another such Person. For the purposes of this definition, the term control as used with respect to a Person shall mean the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
The cost in relation to peoples’ income. For the purpose of the specific WHO glossary quoted here, the daily wage of the lowest-paid unskilled national government worker is used for comparison with the cost of a defined course of treatment for a specific condition. (WHO Access to Medicines Glossary).
The lowest sustainable, competitive price for the Product(s) which covers the cost of raw materials, manufacturing, distribution and operational overheads, and includes a reasonable margin to help ensure the economic sustainability of the production and distribution of the Product(s). (Medicines Patent Pool and Pfizer Sutezolid License Agreement, §3.3).
Collecting, analyzing, and using data to educate and mobilize communities, develop priorities, garner resources, and plan actions to improve public health. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
Alternative One: Information, including data and know-how which is held by participants prior to the accession to this agreement, as well as copyrights or other intellectual and industrial property rights pertaining to such information, and which is necessary for carrying out the project and identified in the project agreement. (IMI 1 JU Model Grant Agreement, §II.1).
Alternative Two: Any data, know-how or information – whatever its form or nature (tangible or intangible), including any rights such as intellectual property rights – that: (a) is held by the beneficiaries before they acceded to the Agreement, and (b) is needed to implement the action or exploit the results. (IMI 2 Model Grant Agreement, §24.1).
Alternative Three: Any information, data, techniques, Know-how, inventions, software, discoveries and materials (regardless of the form or medium in which they are disclosed or stored) which are provided by one Party (whether belonging to that Party or to a third party) to another Party for use in the Project, and whether before or after the date of this Agreement, except any Result. (Lambert Toolkit Model Consortium Agreement D, §1.1).
Alternative one: Any Intellectual Property owned or controlled by a party at the Effective Date or which a party develops or acquires independently of the work under the Project, in each case, which is necessary or useful for undertaking any Work Phase, or the protection or exploitation of Foreground Intellectual Property. (Unattributed Funder Development Partnering Agreement, §1.1.6).
Alternative two: Intellectual Property owned by a party that already exists at the date of this Agreement or is generated other than through the performance of the Services under this Agreement; for the avoidance of doubt, “Background Intellectual Property” of Customer includes without limitation all Intellectual Property assigned or transferred to the Customer under the IP Assignment. (Qinetiq Ltd and Integral Systems Inc Agreement for the Provision of Services).
Any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual property created by You (grantee) or a third party prior to or outside of the Project used as part of the Project. (Gates Foundation Global Access Commitment and Humanitarian License Clauses).
Barriers to receiving needed health care can include cost, language or knowledge barriers, and structural or logistical factors, such as long waiting times and not having transportation. Barriers to care contribute to socioeconomic, racial and ethnic, and geographic differences in health care utilization and health status. (Public Health Accreditation Board, Acronyms & Glossary of Terms, Version 1.5).
(a) In the case of [Contractor], the activities and degree of effort that a company of similar size with a similarly-sized infrastructure and similar resources as [Contractor] would undertake or use in the development and manufacture of a Vaccine at the relevant stage of development or commercialization having regard to the urgent need for a Vaccine to end a global pandemic which is resulting in serious public health issues, restrictions on personal freedoms and economic impact, across the world but taking into account efficacy and safety; and (b) in the case of the [Government Entities], the activities and degree of effort that governments would undertake or use in supporting their contractor in the development of the Vaccine having regard to the urgent need for a Vaccine to end a global pandemic which is resulting in serious public health issues, restrictions on personal freedoms and economic impact, across the world. (European Union and AstraZeneca Advance Purchase Agreement, §1.9).
A mutually beneficial and well-defined relationship entered into by two or more organizations to achieve common goals. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
A product that includes one or more products or other components which are Licensed Products that is sold in combination with one or more separate products or other components which are not Licensed Products and that are sold by Company as stand-alone products. (Trustees of the University of Pennsylvania and Audentes Therapeutics Exclusive License and Collaboration Agreement, §1).
Any sale of a Licensed Product or a Licensed Combination Product to a Third Party in any country in the Territory in the Field; provided, however, that a transfer of Licensed Products or Licensed Combination Products (i) for research and development purposes, or (ii) prior to receipt of Product Approval for use of such Licensed Product or Licensed Combination Product in humans, shall not be considered a Commercial Sale. (“Product Approval” means the grant of all necessary regulatory and governmental approvals required to manufacture, use, store, import, export, transport and/or sell Licensed Products or Licensed Combination Products in any country of the Territory). (Supernus and United Therapeutics Exclusive License Agreement, §1.1 ).
Alternative One: Any and all activities directed to the preparation for sale of, offering for sale of, or sale of a Licensed Product, including activities related to marketing, promoting, distributing, and importing such Licensed Product, and interacting with regulatory authorities regarding any of the foregoing. (AbbVie and Medicines Patent Pool License Agreement, §1.4 ).
Alternative Two: Any and all activities directly and specifically relating to marketing, promoting, detailing, distributing, importing, offering for sale, having sold and/or selling a Licensed Product in the Field in the Territory, but excluding Development and Manufacturing. When used as a verb, “to Commercialize” and “Commercializing” means to engage in Commercialization, and “Commercialized” has a corresponding meaning. (ZP Opco and Eli Lilly Collaboration, Development and License Agreement, Appendix 1.1).
Also see the definition of “Commercialization Plan.”
A confidential plan, no later than [six (6) months] after the first approval of the Product, describing the Targeted Territories to commercialize the Product. (CARB-X Research Subaward Agreement, §6.04).
Also see the definition of “Commercialization.”
The efforts and resources that a similarly situated company or institution, as applicable, would use for its own internally discovered [compounds/assets] of similar commercial potential and similar stage of development, taking into consideration the likely timing of the entry into the market, any patent and other proprietary position and issues of safety and efficacy. (Trustees of the University of Pennslyvania and Biontech Pharmaceuticals GMBH Collaboration & License Agreement, §1.20).
A conformity in fulfilling official requirements. (Merriam Webster Dictionary).
Alternative One: An authorization granted by a government to someone other than the patent-holder to produce the product without the patent-holder’s consent. (Bond, Eric, and Kamal Saggi. “Compulsory Licensing, Price Controls, and Access to Patented Foreign Products.” Protecting Traditional Knowledge, Apr. 2012.)
Alternative Two: The grant of permission for an enterprise seeking to use another’s intellectual property without the consent of its proprietor. (Compulsory Licensing of Patented Inventions, Congressional Research Service report).
Alternative Three: When a government allows someone else to produce a patented product or process without the consent of the patent owner or plans to use the patent-protected invention itself. It is one of the flexibilities in the field of patent protection included in the WTO’s agreement on intellectual property — the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement. (WTO Compulsory Licensing of Pharmaceuticals and TRIPS FAQs).
Alternative Four: Any valid, bona fide compulsory license pursuant to (a) the requirements promulgated under the Agreement or (b) valid laws within such country for any Product. (Gilead HCV License Agreement with Indian Generic Manufacturers, §2.1).
Alternative One: All trade secrets, processes, formulae, data, know-how, improvements, inventions, chemical or biological materials, techniques, marketing plans, strategies, customer lists, or other information that has been created, discovered, or developed by a Party or any of its Affiliates, or has otherwise become known to a Party or any of its Affiliates, as well as any other information and materials that are deemed confidential or proprietary to or by a Party or any of its Affiliates (including all information and materials of a Party’s (or its Affiliates’) customers and any other Third Party and their consultants), regardless of whether any of the foregoing are marked “confidential” or “proprietary” or communicated to the other by the disclosing Party in oral, written, graphic or electronic form. Confidential Information will include the Licensed Manufacturing Know-How. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
Alternative Two: Any and all proprietary Know-How, information and data, including scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by or on behalf of one Party to the other Party and/or its Affiliate in connection with this Agreement. (D3, Biomedical Sciences Institutes and Visterra Agreement for Research Collaboration, §1 ).
Alternative Three: Information, data or material in writing, that the Disclosing Party has prominently marked or otherwise prominently identified as confidential or proprietary in nature. (Aridis and PATH Vaccine Solutions Formulation Development Agreement, §7.1).
Alternative Four: Subject to Section ____, (a) all information provided at any _____ related meeting with respect to any aspect of the Project, regardless of whether or not such information is identified or marked as confidential and regardless of whether or not a written record is subsequently provided if the information was provided orally, and (b) all recorded information, including data marked “Confidential” or bearing a similar legend. (CAVD Data & Materials Sharing Agreement, Annex D).
Possessing of the power to direct or cause the direction of the management and policies of a person whether by membership, ownership, contract or otherwise. “Controlled”, “Controls” and other cognate words and expressions shall be construed accordingly. (KTI Practical Guide Collaborative Research Agreements).
Also see the definition of “Affiliate.”
Alternative One: Factual information (as measurements or statistics) used as a basis for reasoning, discussion, or calculation, information in numerical form that can be digitally transmitted or processed. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5)).
Alternative Two: Recorded information used or generated in the performance of a [Project]. (CAVD Data & Materials Sharing Agreement, Annex B).
The data generated by the holder may not be referred to or used by another person or company for a specific period of time. (WHO, Encouragement of New Clinical Drug Development: The Role of Data Exclusivity).
Generally, nations with underperforming economies, undervalued currency, unstable democratic governments, lack of infrastructure and low standards of education and healthcare. (Global Health Equity Foundation Glossary of Terms).
All activities related to research, pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of applications to regulatory authorities, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a regulatory authority as a condition or in support of obtaining or maintaining a regulatory approval. When used as a verb, “Develop” means to engage in Development. (AbbVie and Medicines Patent Pool License Agreement, §1.5).
The party disclosing Confidential Information to the other Party in connection with the Project. (Medicines Patent Pool and Gilead Amended and Restated License Agreement, §11).
Also see the definition of “Receiving Party.”
The administration form of the completed pharmaceutical product: e.g., tablet, capsule, suspension, injection. (WHO Access to Medicines Glossary).
The occurrence of more cases of disease, injury, or other health condition than expected in a given area or among a specific group of persons during a particular period. Usually the cases are presumed to have a common cause or to be related to one another in some way. (Principles of Epidemiology in Public Health Practice: An Introduction to Applied Epidemiology and Biostatistics. 3rd ed., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), Office of Workforce and Career Development, 2012).
Alternative One: Vaccines, medicines and other products developed, in whole or in part, often with public financial support must be first available to populations when and where they are needed to end an outbreak or manage a disease, regardless of ability to pay, while at a price that is sustainable to the manufacturer. (Huneycutt, Brenda, et al. “Finding Equipoise: CEPI Revises Its Equitable Access Policy.” Vaccine, vol. 38, no. 9, 2020, pp. 2144–2148).
Alternative Two: Equal access for equal need. (Thiede, Michael, and Di McIntyre. “Information, Communication and Equitable Access to Health Care: a Conceptual Note.” Cadernos De Saúde Pública, vol. 24, no. 5, 2008, pp. 1168–1173).
Alternative Three: All individuals have access to affordable, high-quality, culturally and linguistically appropriate care in a timely manner. (Latino Coalition for Healthy California, Equitable Health Care Access).
The adaptation of prices that are charged by the manufacturer or seller to countries with different purchasing power. (WHO, Equitable Access to Essential Medicines: A Framework for Collective Action).
Background Technology that is (i) owned, controlled, or developed by the grantee, or in-licensed with the right to sublicense; and (ii) either incorporated into a Funded Development or reasonably required to exercise the license to Funded Developments. Grantee is required to retain sufficient rights in the Funded Developments and Essential Background Technology to grant this license. Grantee must ensure this license survives the assignment or transfer of Funded Developments or Essential Background Technology. (Gates Foundation Humanitarian License FAQs).
Alternative One: Medicines intended to be available within the context of functioning health systems at all times, in adequate quantities, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and community can afford. (WHO Access to Medicines Glossary).
Alternative Two: Those medicines that satisfy the priority health care needs of the population. (WHO Access to Affordable Medicines).
To make, have made, import, use, sell, or offer for sale, including to research, Develop, Commercialize, register, Manufacture, have Manufactured, hold, or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market, or have sold or otherwise dispose of. (AbbVie and Medicines Patent Pool License Agreement, §1.6).
Alternative One: With respect to a particular Product, any use that is consistent with the label approved by the FDA or applicable foreign regulatory authority in the country of sale for the therapeutic use of such Product. (Medicines Patent Pool and Gilead Amended and Restated License Agreement, §1.6).
Alternative Two: The treatment or prevention of HIV which does not include the treatment or prevention of other viruses, including without limitation HCV. (AbbVie and Medicines Patent Pool License Agreement, §1.7).
Alternative Three: The treatment of any and all therapeutic indications and uses. (Supernus and United Therapeutics Exclusive License Agreement, §1.1).
Alternative Four: [Pediatric treatment] or prevention of disease or other therapeutic area. (AbbVie and Medicines Patent Pool License Agreement, 1.7).
Any formal records of the financial activities and position of a business, person, or other entity.
A report to Funder, of Developers expenditures under the Project Budget report of its activities under the development plan.
Alternative One: Any Intellectual Property (including the Project Patents and Project Inventions) arising out of the undertaking and performance of any Work Phase of the Project. (Unattributed Funder Development Partnering Agreement, §1.1.35).
Alternative Two: Intellectual Property arising out of the performance of the Services under this Agreement (but for the avoidance of doubt excluding Background Intellectual Property). (Qinetiq and Integral Systems Agreement for the Provision of Services, §1.1).
The products, services, processes, technologies, materials, software, data, other innovations, and intellectual property resulting from the Project (including modifications, improvements, and further developments to Background Technology). (Gates Foundation Global Access Commitment and Humanitarian License Clauses).
A country whose three-year average Gross National Income (GNI) per capita is equal to or below the Eligibility Threshold. A Gavi-eligible country is either a Low-Income Country or a Phase 1 Country. (Gavi Alliance Eligibility and Transition Policy, §4.4).
Note: Gavi’s GNI per capita threshold for eligibility was set at an amount of US $1,500 in 2011. The GNI threshold amount for Gavi is updated annually to account for inflation and published on the Gavi website following the annual release of updated GNI p.c. estimates by the World Bank. “Phase 1 Country” means a Gavi-eligible country whose GNI per capita is above the Low Income Country threshold and whose average GNI per capita of the previous three years is equal to or below the Eligibility Threshold.
Any pharmaceutical product usually intended to be interchangeable with the originator brand product, manufactured without a license from the originator manufacturer and marketed after the expiry of patent or other exclusivity rights. (WHO Access to Medicines Glossary).
Alternative One: Requires that grantees and partners commit to making the products and information generated by the foundation funding widely available at an affordable price, in sufficient volume, at a level of quality, and in a time frame that benefits the people. (Gates Foundation, Global Access).
Alternative Two: Requires that (a) the knowledge and information gained from the Project will be promptly and broadly disseminated; and (b) the Funded Developments will be made available and accessible at an affordable price (i) to people most in need within developing countries, or (ii) in support of the U.S. educational system and public libraries, as applicable to the Project. (Gates Foundation Global Access Commitment and Humanitarian License Clauses).
Alternative One: The objectives to provide funding to support the development of drugs and vaccines to address diseases that have a disproportionate impact on people within developing countries, and to ensure that such products can be made available and accessible at reasonable cost and with all due speed to people within developing countries. (Gates Foundation and Visterra Strategic Relationship Letter Agreement).
Alternative Two: Projects will be conducted and managed – along with the resulting products, services, processes, technologies, materials, software, data or other innovations – in a manner that ensures “Global Access.” (Global Health Vaccine Accelerator Platforms Data Sharing Guiding Principles).
Alternative Three: The objectives (a) to improve the processes and technologies for the development, manufacture and delivery of Products for use in the Field, with the aim of making them more available and more accessible in terms of cost, quantity and quality to people most in need in the Developing Countries; and (b) to ensure that information and data resulting from activities under the Project are promptly and broadly disseminated – without jeopardizing intellectual property protection – to the relevant scientific and educational communities. (Redacted Collaboration Agreement, §1.13).
The transnational impacts of globalization upon health determinants and health problems which are beyond the control of individual nations. (WHO Health Promotion Glossary: New Terms).
General statements expressing a program’s aspirations or intended effect on one or more health problems, often stated without time limits. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5)).
A grant of license by a holder of certain intellectual property rights for humanitarian use, usually at a royalty-free basis or at very low costs. As an example, Gates Foundation requires its grantees to grant Gates Foundation a humanitarian license, which is a nonexclusive, perpetual, irrevocable, worldwide, royalty-free, fully paid up, sublicensable license to make, use, sell, offer to sell, import, distribute, copy, create derivative works, publicly perform and display Funded Developments and Essential Background Technology. (Gates Foundation Humanitarian License FAQs).
Alternative One: Any and all improvements, enhancements or modifications, patentable or otherwise, relating to the Compound or Licensed Products or Licensed Combination Products including, without limitation, any change or modification in the manufacture, formulation, analytical methodology, ingredients, preparation, presentation or means of delivery, administration or dosage of the Compound or Licensed Products or Licensed Combination Products. (Supernus and United Therapeutics Exclusive License Agreement, §1.1).
Alternative Two: All improvements, methods, modifications and other know-how developed by or on behalf of a Licensee and relating to a Product. (Medicines Patent Pool and Gilead Amended and Restated License Agreement, §11).
Anything that encourages a party to do something or to work harder. (Global Health Learning Center Glossary).
Alternative One: When, having considered all reasonably accessible and relevant information including epidemiological data, travel and migration patterns and the likely availability of other products or product candidates, there is a determination that there is a heightened need for a Product. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, §16).
Alternative Two: When, having considered all reasonably accessible and relevant information including epidemiological data, travel and migration patterns and the likely availability of other products or product candidates in the Field, Funder determines, in its sole discretion, that there is a heightened need for the Product. (Unattributed Funder Development Partnering Agreement, §1.1.41).
Any communication or reception of knowledge or intelligence; knowledge obtained from investigation, study, or instruction: intelligence, news, facts, data. (Merriam Webster Dictionary).
(a) Having generally ceased to pay debts in the ordinary course of business other than as a result of bona fide dispute, (b) being unable to pay debts as they become due, or (c) being insolvent within the meaning of federal bankruptcy law. (Code of the District of Columbia, § 28:1-201(b)(23))
Alternative One: All intellectual property rights arising from or associated with the following, whether created, protected or arising under the laws of the United Kingdom or any other jurisdiction:
(a) trade names, trademarks and service marks (whether registered or unregistered), domain names and other internet addresses or identifiers, trade dress and similar rights and applications to register any of the foregoing (collectively, “Marks”);
(b) patents and patent applications and rights in respect of utility models or industrial designs (collectively, “Patents”);
(c) copyrights (whether registered or unregistered) and registrations and applications therefor (collectively, “Copyrights”);
(d) know-how, inventions, discoveries, methods, processes, techniques, methodologies, formulae, algorithms, technical data, specifications, research and development information, technology, data bases and other proprietary or confidential information, including customer lists, in each case that derives economic value (actual or potential) from not being generally known to other persons who can obtain economic value from its disclosure, but excluding any Copyrights or Patents that cover or protect any of the foregoing (collectively, “Trade Secrets”); and
(e) any other proprietary, intellectual or industrial property rights of any kind or nature that do not comprise or are not protected by Marks, Patents, Copyrights or Trade Secrets. (Qinetiq and Integral Systems Agreement for the Provision of Services, §1.1).
Alternative Two: Any or all of the following and all rights in, arising out of, or associated therewith:
(a) all United States and foreign patents and utility models and applications therefor and all reissues, divisions, renewals, reexaminations, extensions, provisionals, continuations and continuations-in-part thereof, and equivalent or similar rights anywhere in the world in inventions, disclosures, and discoveries, whether or not patentable, and whether or not reduced to practice (“Patents”);
(b) all trade secrets, know-how, proprietary information, technical data, improvements, technology, computer programs (in source code and executable code form, and whether embodied in software, firmware or otherwise), documentation (including software documentation), drawings, designs, flow charts, specifications, logic diagrams, programmer notes, protocols, files, records, databases, formulae, compositions, processes, manufacturing and production processes and techniques, research and development information, improvements, proposals, and technical data (“Technical Information”);
(c) all copyrights, works of authorship, copyright registrations and applications therefor and all other rights corresponding thereto throughout the world (“Copyrights”);
(d) all industrial designs and any registrations and applications therefor throughout the world;
(e) any similar, corresponding or equivalent rights to any of the foregoing anywhere in the world, including but not limited to computer program rights and registrations and applications therefor; and
(f) all copies and tangible embodiments of the foregoing (in whatever form or media). (Intersil and ChipPAC Intellectual Property Rights Agreement, §1.3).
Alternative Three: All rights in Copyrights, Patents, Mask Works, Trademarks, Technology and any other proprietary rights relating to intangible property anywhere in the world, and all registrations and applications related to any of the foregoing and analogous rights thereto anywhere in the world. (Motorola and Freescale Semiconductor Intellectual Property Assignment Agreement, §1.12).
Alternative Four: Means any worldwide intellectual property or other proprietary rights (excluding trademark, service mark, and domain name rights), including but not limited to copyrights, trade dress rights (including audible characteristics), mask work rights registrations, moral rights, patent rights, patent applications and disclosures, know-how, inventions, rights of priority, and trade secret rights. (TGC, Tivo Intl II, and Tivo Intellectual Property and Technology Agreement, §1.63).
Alternative Five: patents, patent applications, inventions, Know-how, trade secrets and other confidential information, rights in design (registered and unregistered), copyright (including, without limitation, rights in computer software), data, database rights and sui generis rights, rights affording equivalent protection to copyright, semiconductor topography rights, trade marks, service marks, logos, domain names, business names, trade names, brand names, certification marks, assumed names and other indicators or origin, rights in any drawings, designs, plans, specifications, manuals, computer software, assets, inventor’s certificates and invention disclosures, writings and other works, whether copyright or not, bills of material, moral rights and all other industrial or intellectual property or other rights or forms of protection of a similar nature or having similar effect in any part of the world and rights in and in relation to them and, where appropriate, applications for any of them in any country or jurisdiction, rights in the nature of unfair competition rights, rights to sue for passing-off, the right to apply for any of them and all other information necessary for the technical exploration of any of the same and all registrations. (Forfás, Template Collaboration Agreements).
Products within a therapeutic class, but with different active ingredients are interchangeable if they have equivalent therapeutic effect. (WHO Access to Medicines Glossary).
A common, generic name selected by designated experts for the unambiguous identification of a new pharmaceutical substance. The selection process is based on a procedure and guiding principles adopted by the World Health Assembly. INNs are recommended for worldwide use. (Health Action International Glossary).
A biological standard accepted by WHO for use as an International Reference Preparation. (WHO Blood Product and Related Biologicals, International Reference Materials).
A product that has not received marketing approval. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, §14).
Any Program Know-How (and Program Patent Rights that claim or cover such Program Know-How) that is conceived, discovered or reduced to practice by one or more employees, agents or consultants of [Party A], its Affiliates, or its subcontractors, together with one or more employees, agents or consultants of [Party B], its Affiliates, or its subcontractors. (Merck and Bioprotection Systems License and Collaboration Agreement, §7.2).
Any Program Patent Rights that claim or cover such Joint Program Know-How that is conceived, discovered or reduced to practice by one or more employees, agents or consultants of [Party A], its Affiliates, or its subcontractors, together with one or more employees, agents or consultants of [Party B], its Affiliates, or its subcontractors. (Merck and Bioprotection Systems License and Collaboration Agreement, §7.2).
Any Project IP which is conceived or reduced to practice, authored or contributed to, during activities carried out jointly by or on behalf of two (2) or more Parties under the Agreement. (Redacted Collaboration Agreement, §8.1(ii)).
Any unpatented, unpublished, technical information (including, without limitation, information relating to inventions, discoveries, concepts, methodologies, models, research, development and testing procedures, the results of experiments, tests and trials, manufacturing processes, materials, formulae, formulations, processes, research or experimental results, techniques and specifications, quality control data, analyses, reports and submissions) that is not in the public domain. (Forfás, Template Collaboration Agreements).
The aggregate of statutes, ordinances, regulations, rules, judicial decisions, and accepted legal principles that the courts of a particular jurisdiction apply in deciding controversies brought before them. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5)).
Alternative One: A list of developing countries that, according to the United Nations, exhibit the lowest indicators of socioeconomic development, with the lowest Human Development Index ratings of all countries in the world. (United Nations, General Assembly Twenty-Sixth Session (1971)).
Alternative Two: The countries listed on the United Nations List of Least Developed Countries. (UNCTAD, UN List of Least Developed Countries).
Alternative One: Pharmaceutical compositions comprised of the Compound as a therapeutically active ingredient in combination with other active ingredients and which uses or is developed or manufactured using or in connection with the [licensed] Intellectual Property. (Supernus and United Therapeutics Exclusive License Agreement, §1.1).
Alternative Two: Pharmaceutical combinations and compositions that have been prepared and are in a tablet form containing [compound] ready for administration to Adult Patients solely for [indication] which contain the [compound] as an active ingredient in combination with (a) the [another specified compound] and/or (b) other active ingredients, and in each case where the resulting combination product has been recommended by the World Health Organisation for supply to and use by Adult Patients. (Medicines Patent Pool and Zhejiang Huahai License Agreement, §1.24).
Also see the definition of “Licensed Mono Products.”
The compound listed in [Schedule]. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
All technical information and know-how known to or Controlled by [Licensor] or its Affiliates as of the Effective Date (including all manufacturing data, the percentages and specifications of ingredients, the manufacturing process, specifications, assays, quality control and testing procedures) that is identified by [Licensor] as primarily and directly relating to, and reasonably necessary for, the making of the Licensed Products in the same manner that such Licensed Products have been made by [Licensor] prior to the Effective Date. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
Pharmaceutical compositions that are in a tablet form containing [compound] which have been prepared and are ready for administration to Adult Patients solely for [indication] which contain the [compound] as their sole active ingredient. (Medicines Patent Pool and Zhejiang Huahai License Agreement, §1.25)
Also see the definition of “Licensed Combination Products.”
(a) the patents and patent applications of ____ in the Territory related to the Licensed Compound;
(b) any continuation, continuation-in-part (but only to the extent that such application includes new data in support of claims previously submitted in a prior originally filed application), divisional, and continued-prosecution applications of any patent applications included in paragraph (a);
(c) any patents issuing from any patent applications included in the paragraphs (a) and (b);
in each case, including any renewals, extensions, patents of addition, supplementary protection certificates, revivals, re-examinations, and reissues thereof. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
Alternative One: Any human pharmaceutical products produced under license from ____ and/or ____ in the Field and containing the Licensed Compound as one of its active ingredients (or as its sole active ingredient), in finished form or in such other forms, presentations, doses and formulations. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
Alternative Two: Pharmaceutical compositions comprised of the Compound as the therapeutically active ingredient and which uses or is developed or manufactured using or in connection with the [licensed] Intellectual Property. (Supernus and United Therapeutics Exclusive License Agreement, §1.1).
One to whom or to which a license is granted. (Your Dictionary, Licensee).
One who grants a license. (Your Dictionary, Licensor)
Those countries defined by the Organisation for Economic Co-operation and Development as low and middle income countries based on gross national income (GNI) per capita as published by the World Bank. (OECD, DAC List of ODA Recipients).
All activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, and holding of the Licensed Product, or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance, and quality control. (AbbVie and Medicines Patent Pool License Agreement, §1.10).
The process of making employees and consultants available to a party [as part of the technology transfer process] to provide consultation and technical assistance in order to ensure an orderly transition of the manufacturing technology and operations in the start-up of its manufacture of Compound and Product. (Merck Sharp & Dohme and Chimerix Collaboration and Exclusive License Agreement, §3.2.2).
Also see the definition of “Technology Transfer.”
A certain percentage added to a purchasing price to cover the cost and profit of the distributor, wholesaler, retailer, medical store etc. (WHO Access to Medicines Glossary).
An official document issued by a regulatory authority for the purpose of marketing or free distribution of a product after evaluation for safety, efficacy and quality. (WHO Access to Medicines Glossary).
Also see the definition of “Regulatory Approval.”
A fixed period of time following drug approval during which the sponsor can market their drug without direct competition from manufacturers of duplicate or reformulated products. (Burch, Brandon. “Types of Marketing Exclusivity in Drug Development.” Nuventra, 2019.)
All types of tangible chemical, biological and/or physical materials. (IMI 2 Joint Undertaking Model Consortium Agreement, §9).
Any dosage form containing a substance approved for the prevention and treatment of disease. (WHO Access to Medicines Glossary).
Refers to measures taken to reduce the harmful effects of a disaster or emergency by attempting to limit the impact on human health and economic infrastructure. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5)
A profit margin comparable to the profit margins commonly agreed to by [Global Health Organization] in its collaborative research and development agreements for the supply of any resulting products to Public Sector Agencies for distribution in the public sector of developing countries. (Alternative Provisions for Publicly Funded Medicines and Vaccines).
Alternative One: with respect to a given calendar quarter, the total amount invoiced by a Sublicensee for sales of the Licensed Products in the countries within the Territory where Licensed Patents Rights are in force, less freight, insurance, packing, shipping and custom duty, VAT, excise tax, sales tax, and packing for shipment, to the extent consistent with generally accepted accounting principles as consistently applied across all products of the Sublicensee and in line with the deductions reasonably expected in the relevant market. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
Alternative Two: the gross consideration invoiced or received by Licensee or any of its Affiliates or Sublicensees for Sales of Licensed Product (including any cash amounts plus the fair market value of any other forms of consideration), less the following deductions (to the extent included in and not already deducted from the gross amounts invoiced or otherwise charged) to the extent reasonable and customary and solely related to the sale of the Licensed Product:
- trade discounts, including trade, cash and quantity discounts or rebates, credits or refunds;
- allowances or credits granted upon claims, returns or rejections of products, including recalls, regardless of the party requesting such recall;
- charges included in the gross sales price for freight, insurance, transportation, postage, handling and any other charges relating to the sale, transportation, delivery or return of such Licensed Product;
- customs duties, sales, excise and use taxes and any other governmental charges (including value added tax) actually paid in connection with the transportation, distribution, use or sale of such Licensed Product (but excluding what is commonly known as income taxes);
- rebates and chargebacks or retroactive price reductions made to federal, state or local governments (or their agencies), or any Third Party payor, administrator or contractor, including managed health organizations; and
- payments required by law to be made under Medicaid, Medicare or other government special medical assistance programs (including, but not limited to, payments made under the new “Medicare Part D Coverage Gap Discount Program” and the “Annual Fee on Branded Pharmaceutical Manufacturers”, specific to the Licensed Product for which the deduction is taken).
Even if there is overlap between any of deductions described above, each individual item shall only be deducted once in the overall Net Sales calculation. Each of the above deductions to Net Sales shall be calculated in accordance with the Accounting Standards (with the applicable Accounting Standard used clearly indicated on any reports).
In the event that the Licensed Product is sold as a Combination Product, Net Sales will be determined by multiplying Net Sales of such Combination Product by the fraction A/(A+B), where A is the invoice price of the Licensed Product, when sold separately, and B is the invoice price of any other therapeutically active ingredient(s) in the combination, when sold separately, in each case in the same country and similar class, purity and dosage as in the Combination Product. If, on a country-by-country basis, the Licensed Product or the other therapeutically active ingredient that is not a Product in the Combination Product is/are not sold separately in such country, Net Sales shall be determined by multiplying actual Net Sales of such Combination Product by the fraction C/(C+D), where C is the fair market value of the Licensed Product portion of such combination and D is the fair market value of the other therapeutically active ingredient that is not a Product (such fair market value is to be determined by mutual agreement of the Parties or, in the absence of such mutual agreement, by a neutral Third Party). (Trustees of the University of Pennsylvania and BioNTech RNA Pharmaceuticals Collaboration & License Agreement, §1.46).
Targets for achievement through interventions. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
The practice of providing online access to scientific information that is free of charge to the end-user and reusable. (EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing, §5).
The performance of a practical work or of something involving the practical application of principles or processes. (Merriam Webster Dictionary).
The difference in price between the originator brand and a generic equivalent. (WHO Access to Medicines Glossary).
A product that was first authorized worldwide for marketing (normally as a patented product) on the basis of the documentation of its efficacy, safety and quality, according to requirements at the time of authorization. (WHO Access to Medicines Glossary).
Countries that are not the key countries where the Product is intended to be marketed. (CARB-X Research Subaward Agreement, §6.04).
Also see the definition of “Targeted Territory.”
Alternative One: a Public Health Emergency of International Concern declared by WHO or a public health emergency on a national or regional scale declared by one or more national governments and in each case for a material increase in the number of cases of people infected in the Field including any regional outbreak, an epidemic or a pandemic. (Unattributed Funder Development Partnering Agreement, §1.1.57).
Alternative Two: the occurrence of disease cases in excess of normal expectancy. The number of cases varies according to the disease-causing agent, and the size and type of previous and existing exposure to the agent. (WHO Environment, Climate Change and Health: Disease Outbreaks).
Alternative Three: the occurrence of more cases of disease, injury, or other health condition than expected in a given area or among a specific group of persons during a specific period. Usually, the cases are presumed to have a common cause or to be related to one another in some way. Sometimes distinguished from an epidemic as more localized, or the term less likely to evoke public panic. (Principles of Epidemiology in Public Health Practice: An Introduction to Applied Epidemiology and Biostatistics. 3rd ed., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), Office of Workforce and Career Development, 2012).
A notice, in writing in the event of an Outbreak. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, §16).
Include: (i) develop the Product in accordance with the Development Plan and as more particularly detailed in the Work Phase Statements; (ii) provide free of charge or at a discounted rate the services and facilities outlined in Schedule 3 in accordance with the timeframe (if any) set out at Schedule 3, the Application, and in more detail in specific Work Phase Statements; and (iii) use its Reasonable Efforts either to establish directly or to enter into an agreement with Funder, a Public Sector Agency or another third party, for supply of Product into an Investigational Stockpile before the first subject receives the first dose in a Phase II Clinical Trial and perform the related obligations. (Unattributed Funder Development Partnering Agreement, §3.2).
Include: (i) the collection and sharing of trial subject information in accordance with Funder Policies, including information about pathogens such as sequence data; (ii) engagement with affected communities to establish mutual trust; (iii) integration of Partner research efforts into Public Sector Agencies’ epidemic response; (iv) manufacture of additional investigational doses of Product (if necessary) or manufacture to replenish Investigational Stockpile; (v) negotiation of clinical trial contracts; (vi) performance of independent ethics reviews; and (vii) implementation of prepared clinical trial designs. (Unattributed Funder Development Partnering Agreement, §1.1.59).
An epidemic occurring over a widespread area (multiple countries or continents) and usually affecting a substantial proportion of the population. (Principles of Epidemiology in Public Health Practice: An Introduction to Applied Epidemiology and Biostatistics. 3rd ed., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), Office of Workforce and Career Development, 2012).
Also see the definition of “Outbreak.”
A relationship among individuals and groups that is characterized by mutual cooperation and responsibilities. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
Alternative One: any and all patents and patent applications in the Territory (which for the purpose of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention), including divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates, and the like of any such patents and patent applications, and foreign equivalents of the foregoing. (Law Insider Dictionary).
Alternative Two: a title granted by public authorities that confers a temporary monopoly for the exploitation of an invention upon the person who reveals it, furnishes a sufficiently clear and full description of it, and claims this monopoly. (WHO Access to Medicines Glossary).
Any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture, governmental authority, association or other entity or other form of business organization. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
Products with identical amounts of the same active ingredient in the same dosage form and route of administration, that meet the standards of strength, quality, purity and identity. (WHO Access to Medicines Glossary).
Any product intended for human use, presented in its finished dosage form that is subject to control by pharmaceutical legislation (registered). (WHO Access to Medicines Glossary).
The general principles by which a government entity is guided in its management of public affairs. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
A voucher issued by FDA to the sponsor of a rare pediatric disease product application at the time of the marketing application approval pursuant to section 529 of the Federal Drug and Cosmetic Act, which entitles the holder to designate a single human drug application submitted under section 505(b)(1) of the FDCA or section 351 of the Public Health Service Act as qualifying for a priority review. (Law Insider Dictionary).
Note: Read more about Priority Review Vouchers here. Note that priority review voucher may also apply to products intended to treat tropical diseases or to medical countermeasures to terrorism.
The price paid by the government, wholesalers, retailers and other purchasers to procure medicines. Different prices may be paid for the same product by a public sector purchaser, such as the Ministry of Health, the medicine outlet that supplies the medicine to the patient, and the individual who purchases the medicine. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
The recommendations for and limitations upon use of a pharmaceutical product that must be included in product labeling and packaging pursuant to any Regulatory Approval for such product. (Law Insider Dictionary).
Any Know-How (including any Compounds) that is first conceived, discovered, made and/or reduced to practice (as would be necessary to establish inventorship under United States patent law (regardless of where the applicable activities occurred)) by or on behalf of either Party or its Affiliate (or their respective employees, agents or consultants) or jointly by both Parties or their respective Affiliates (or their respective employees, agents or consultants) in performing the Transition Program or other activities under this Agreement. (License and Collaboration Agreement between Merck and Bioprotection Systems Corp, §7.2).
All data and information, including all clinical study data, produced or arising as a result of the Project. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, §11)
Any discoveries, inventions, know-how, patents, trademarks and other forms of intellectual property that arise under the Project. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, §13.2).
Any discovery, development, Know-How, invention or improvement created, devised or arising out of the undertaking and performance of any Work Phase. (Unattributed Funder Development Partnering Agreement, §1.1.67).
The expiration of the last patent or exclusivity periods in the United States, the European Union or Japan for any Project IP Rights. (CARB-X Research Subaward Agreement, §5.01(f)(iii)).
Biological samples, vaccines (including Product), animal models and other tangible materials produced under the Project [that are shared between the parties under the applicable agreements]. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, §12).
Any patent applications made which claim any Project Inventions, any patents resulting from any such applications, utility certificates, improvement patents and models and certificates of addition and all foreign counterparts of them in all countries, including any divisional applications and divisional patents, refiling, renewals, continuations, continuations-in-part, patents of addition, extensions (including patent term extensions), reissues, substitutions, confirmations, registrations, revalidations, pipeline and administrative protections and additions, and any equivalents of the foregoing in any and all countries of or to any of them, as well as any supplementary protection certificates and equivalent protection rights in respect of any of them. (Unattributed Funder Development Partnering Agreement, §1.1.68).
The outcomes and results of the Project, may comprise biological samples, data, intellectual property, materials, any Product and Investigational Product, publications, reference standards, technology and other results and shall include all Project IP, Project Data and Project Materials. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, §10.1).
A non-exclusive, fully paid-up, sublicensable and worldwide license under the Project Results and Enabling Rights to develop, manufacture, market and/or supply the Product worldwide; in each case for use in preparation for or response to an Outbreak or Increased Outbreak Preparation Need. For the purposes of this definition, the term “Product” shall mean the [Vaccine] in any form or dosage of pharmaceutical composition or preparation for use in humans. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, Schedule A).
Also see the definition of “Humanitarian License.”
Includes general government and public corporations. Quasi-corporations owned by government units are grouped with corporations in the nonfinancial or financial corporate sectors, thus part of public corporations (2008 System of National Accounts). (OECD (2019), “Glossary”, in Government at a Glance 2019, OECD Publishing).
Any written, oral or other public disclosure of Results, including the public use or sale of an invention based on the Results. (Forfás, Template Collaboration Agreements).
Any data concerning information that is difficult to measure, count, or express in numerical terms. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
Any data concerning information that can be expressed in numerical terms, counted, or compared on a scale. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
A bulk refund that pharmacies may receive from a wholesaler, based on sales of a particular product or total purchases from that wholesaler over a particular period of time. It does not affect the price the patient pays, but the retailer’s profits will be higher. (WHO Access to Medicines Glossary).
The party receiving Confidential Information from the other Party in connection with the Project. (Medicines Patent Pool and Gilead Amended and Restated License Agreement, §11).
Also see the definition of “Disclosing Party.”
Any technical, medical, scientific or other license, registration, authorization or approval of any Regulatory Authority necessary for the development, manufacture or commercialization of a pharmaceutical product in any regulatory jurisdiction. (Medicines Patent Pool and Pfizer Sutezolid License Agreement, §1.10)
Any national or supranational governmental authority that has responsibility in the Territory over the Development and/or Commercialization of the Licensed Compound and Licensed Products. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
All applications, registrations, licenses, authorizations and approvals (including all Marketing Authorizations), all correspondence submitted to or received from Regulatory Authorities (including [*]) and all supporting documents in connection therewith, and all reports and documentation in connection with clinical studies and tests (including [*]), and [*] in any of the foregoing, including all INDs, BLAs, [*], in each case related to a Compound and/or Product. (Merck and Bioprotection Systems License and Collaboration Agreement, §2.9.2).
Also see the definition of “Regulatory Approval”.
Any written or spoken description of a situation, event, etc.; an official document that gives information about a particular subject. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
Alternative One: quantitative data, methodology and analysis. (Global Health Equity Foundation, Glossary of Terms)
Alternative Two: a systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalized knowledge. (Public Health Accreditation Board Acronyms & Glossary of Terms, Version 1.5).
Any information, in particular facts or numbers, collected to be examined and considered as a basis for reasoning, discussion, or calculation. (Horizon 2020 Online Manual, Cross-Cutting Issues, Open Access & Data Management).
The use of results or background needed to use results, for all purposes other than for completing the action or for direct exploitation, and which includes but is not limited to the application of results as a tool for research, including clinical research and trials, and which directly or indirectly contributes to the objectives set out in the Societal Challenge health, demographic change and well-being. (IMI 2 Joint Undertaking Model Consortium Agreement, §1).
Any (tangible or intangible) output of the action such as data, knowledge or information — whatever its form or nature, whether it can be protected or not — that is generated in the action, as well as any rights attached to it, including intellectual property rights. (IMI 2 Model Grant Agreement, §26.1).
A percentage added to the purchasing price to cover the retailer’s costs and profit. (WHO Access to Medicines Glossary).
A company that sells goods to consumers. (WHO Access to Medicines Glossary).
Tangible or intangible output generated by a beneficiary under the action, such as data, knowledge and information whatever their form or nature, whether or not they can be protected, but which are outside of the action objectives as defined in this Agreement and which therefore are not needed for implementing the action or for research use of results. (IMI 2 Model Grant Agreement, §26.1)
Any pharmaceutical composition which infringes the Foreground Intellectual Property. (Unattributed Funder Development Partnering Agreement, §11.2.3).
The right of the funder to assume the development and commercialization of the funded products in the event of the actual or anticipated failure by the grantee/developer to develop or commercialize the funded products to ensure access and affordability thereof in the applicable field and territory.
Alternative One: the wide range of functions carried out by governments as they seek to achieve national health policy objectives. (WHO: Health Systems – Stewardship).
Alternative Two: the careful and responsible management of the well-being of the population. (WHO World Health Report 2000, Health systems : improving performance).
When the Product enters Phase III trials, the Subrecipient shall create a plan reasonably describing how it intends to meet the stewardship and access obligations for the Product. The Stewardship and Access Plan shall not include confidential business information and shall include:
(a) Strategy to support access and stewardship (e.g. proposed reliable production with sufficient capacity, supply systems, the broad approach to product labelling, and the broad approach to ensure economic barriers to access are as low as reasonably possible);
(b) Identifying obstacles and constraints to access and stewardship;
(c) Exploitation strategy for Project IP Rights, including whether it is planned for the Project IP Rights to be transferred to a third party;
(d) Strategy to ensure marketing approvals are received for key territories in a timely manner; and
(e) Strategy for monitoring effectiveness of access and stewardship, including proposed metrics to measure success.
Note: see the CARB-X Stewardship & Access Plan Guide for further information.
An intellectual property right that serves as an extension to a patent right. They apply to specific pharmaceutical and plant protection products that have been authorised by regulatory authorities. (European Commission: Internal Market, Industry, Entrepreneurship and SMEs).
Outlines the desired “profile” or characteristics of a target product that is aimed at a particular disease or diseases. TPPs state intended use, target populations and other desired attributes of products, including safety and efficacy-related characteristics. (WHO: Global Observatory on Health R&D).
Also see the definition of “Other Territories.”
Promptly and diligently providing all necessary guidance, information, materials and assistance reasonably required by the [Licensee] to accomplish the activities that may be requested by the Agreement. (Gilead HCV License Agreement with Indian Generic Manufacturers, §5.5).
Also see the definition of “Manufacturing Consultation.”
Alternative One: the countries set forth in [Schedule]. (Medicines Patent Pool and Gilead Amended and Restated License Agreement, §12).
Alternative Two: the countries listed in [Schedule] and such other or different countries as the Parties may agree in writing. (Medicines Patent Pool and Bristol-Myers Squibb Company License and Technology Transfer Agreement, §1.1).
Any person or entity who or which are neither a Party nor an Affiliate of a Party. (Supernus and United Therapeutics Exclusive License Agreement, §1.1 ).
When companies charge different prices for the same product depending on the class of purchaser. (WHO, WIPO, WTO, Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade, 2020).
An agreement annexed to the World Trade Organization convention aimed at strengthening and harmonizing aspects of the protection of intellectual property at the global level. It includes trademarks and patents as well as other forms of intellectual property. (WHO Access to Medicines Glossary).
A group of independent experts who are not involved in the clinical study that will approve the clinical study protocol and monitor the progress of the clinical trial, including any changes to the protocol. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, Schedule A).
A third party, that is capable of performing the work and would be prepared to undertake activities in the event that Awardee declines [funder’s] request to do so, or if Awardee and [funder] do not reach agreement on a new Work Package. (CEPI CfP3i Program Funding Agreement and Terms and Conditions, §16.4).
The World Health Organization.
A systematic process to determine the capacity of a manufacturer to produce a product of consistent quality in accordance with international standards and WHO/UNFPA specifications. The purpose of prequalification is to protect the buyer and the end user by ensuring good quality products are procured and distributed. (WHO: Reproductive Health Essential Medicines).
A percentage added to the purchasing price to cover the wholesaler’s costs and profit. (WHO Access to Medicines Glossary).
A company that buys goods from a manufacturer or importer and sells it to retailers. (WHO Access to Medicines Glossary).